Literature DB >> 19940422

Clinical review of hereditary angioedema: diagnosis and management.

Mark Weis1.   

Abstract

Hereditary angioedema (HAE) is caused by a deficiency in C1 esterase inhibitor and is characterized by sudden attacks of edema associated with discomfort and pain. The disease places patients at risk for disability and death if left untreated. Symptom severity and frequency can be extremely variable even among affected members of the same family. Attacks are not associated with inflammation or allergy, with most occurring secondary to trauma or stress. Swelling can affect any part of the body or multiple sites at once. Commonly affected areas include the extremities, genitalia, trunk, gastrointestinal tract, face, and larynx. Swelling typically worsens over 24 to 36 hours and resolves within 48 hours in less severe cases. Attacks result in 15,000 to 30,000 emergency department visits each year. Many of these emergency cases will undergo unnecessary surgeries or medical procedures due to misdiagnosis. The hallmarks of HAE--recurrent episodes of swelling without urticaria, a family history of HAE, first attack in childhood, and worsening at puberty--can be identified by a thorough family history, and the diagnosis can be confirmed by laboratory studies. Nevertheless, diagnosis may be delayed by 2 decades. We review available therapies and clinical characteristics that will both help clinicians diagnose HAE and distinguish among emergencies and nonemergency cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19940422     DOI: 10.3810/pgm.2009.11.2071

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1.  Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema.

Authors:  Jonathan A Bernstein; Suzanne Coleman; Arturo J Bonnin
Journal:  J Cardiothorac Surg       Date:  2010-10-18       Impact factor: 1.637

2.  Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.

Authors:  A Malbrán; M Riedl; B Ritchie; W B Smith; W Yang; A Banerji; J Hébert; G J Gleich; D Hurewitz; K W Jacobson; J A Bernstein; D A Khan; C H Kirkpatrick; D Resnick; H Li; D S Fernández Romero; W Lumry
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

3.  A case of hereditary angioedema in a 7-year-old korean girl.

Authors:  Meeyong Shin; Kangmo Ahn
Journal:  Allergy Asthma Immunol Res       Date:  2012-08-23       Impact factor: 5.764

4.  Coexistence of hereditary angioedema in a case of familial Mediterranean fever with partial response to colchicine.

Authors:  Semiha Erdem Bahceci; Ferah Genel; Nesrin Gulez; Hikmet T Nacaroglu
Journal:  Cent Eur J Immunol       Date:  2015-04-22       Impact factor: 2.085

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.